FMF is not always "fever": from clinical presentation to "treat to target"

Maria Cristina Maggio1, Giovanni Corsello2

  • 1Department of Health Promotion Sciences Maternal and Infantile Care, Internal Medicine and Medical Specialities "G. D'Alessandro", University of Palermo, Palermo, Italy. mariacristina.maggio@unipa.it.

Insights

Familial Mediterranean Fever (FMF) is an autoinflammatory disease caused by MEFV gene mutations, leading to recurrent fever and inflammation. Early diagnosis and treatment with colchicine or biologics are crucial for managing FMF and preventing complications.

Area of Science:

  • Genetics and Immunology
  • Pediatric Rheumatology
  • Autoinflammatory Diseases

Background:

  • Familial Mediterranean Fever (FMF) is a monogenic autoinflammatory disorder stemming from MEFV gene mutations.
  • It involves inflammasome dysregulation, leading to interleukin-1 overproduction and recurrent inflammatory attacks.
  • Symptoms often manifest before age 20, with earlier onset correlating to a more severe phenotype.

Purpose of the Study:

  • To provide pediatricians with a comprehensive review of Familial Mediterranean Fever.
  • To cover diagnostic, clinical, and therapeutic aspects of FMF.
  • To emphasize the importance of accurate diagnosis and management strategies.

Main Methods:

  • Review of clinical manifestations, including fever, serositis, and arthritis.
  • Discussion of diagnostic approaches, encompassing clinical criteria and genetic confirmation.
  • Analysis of treatment strategies, focusing on colchicine and biological agents.

Main Results:

  • FMF attacks are characterized by fever, serositis, arthritis, and elevated inflammatory markers.
  • Diagnosis requires clinical definition and genetic confirmation, with established criteria like Tel Hashomer and PRINTO.
  • Treatment aims to prevent attacks, normalize inflammation, and avert long-term complications such as amyloidosis.

Conclusions:

  • Accurate differential diagnosis is essential to distinguish FMF from other inflammatory conditions.
  • Colchicine is the primary treatment, with biological drugs available for non-responders.
  • Effective management of FMF is vital for preventing disease progression and improving patient outcomes.

Related Concept Videos

Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
218
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
142
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.4K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K